

**EDUCATIONAL COURSE:
Preclinical and early-phase clinical pharmacology
6th February 2019**



**40th EORTC-PAMM Winter Meeting
7th – 9th February 2019**

**Palazzo della Gran Guardia, piazza Bra
Verona - Italy**

PAMM Board

Eric Raymond, France, Chair

Annette Larsen, France

Elisa Giovannetti, The Netherlands

Godefridus J. Peters, The Netherlands

Scientific Committee

Andrea Bonetti, Italy

Brian Leyland-Jones, USA

Etienne Chateleut, France

Paola Perego, Italy

Joseph Ciccolini, France

Godefridus J. Peters, The Netherlands

Elisa Giovannetti, The Netherlands

Roger M. Phillips, UK

Monika Hegi, Switzerland

Eric Raymond, France

Georg Hempel, Germany

Christian Rolfo, Belgium

Markus Joerger, Switzerland

Andrzej Skladanowski, Poland

Annette Larsen, France

Andrew D. Westwell, UK

Roberto Leone, Italy

Nadia Zaffaroni, Italy

Local Organizing Committee

Andrea Bonetti and Roberto Leone



Department of Oncology Mater Salutis
Hospital Legnago



UNIVERSITÀ
di VERONA

Department of Diagnostic and Public Health,
Section of Pharmacology, University of Verona

Sponsorship and Cooperation



AZIENDA OSPEDALIERA
UNIVERSITARIA INTEGRATA
VERONA



In cooperation with



ESO Recommended Event



EDUCATIONAL COURSE: PRECLINICAL AND EARLY-PHASE CLINICAL PHARMACOLOGY

Chairs: Paola Perego, Molecular Pharmacology Unit, Istituto Nazionale dei Tumori Milano, Italy
Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

9.00-9.25 **How to perform pharmacological studies in vitro**
Paola Perego, Molecular Pharmacology Unit, Istituto Nazionale dei Tumori Milano, Italy

9.25-9.50 **To combine or not to combine: drug interactions and tools for their analysis**
Godefridus J. Peters, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

9.50-10.15 **Realistic preclinical approaches: hypoxia and 3D models**
Roger Phillips, School of Applied Sciences, University of Huddersfield, Huddersfield, UK

10.15-10.30 *Coffee break*

10.30-10.55 **How to navigate among the -OMICS data and their correlation with pharmacological data**
Giovanni Ciriello, Department of Computational Biology, University of Lausanne, Lausanne, Switzerland

10.55-11.20 **Drug development, after the NCI-compounds initiative**
Hans Hendriks, Hendriks Pharmaceutical Consulting, Purmerend, The Netherlands

11.20-11.45 **Neighborhood matters: new tools and practical approaches for co-culturing cancer cells**
Elisa Giovannetti, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

11.45-12.45 **Practical session on data analysis and technical aspects**

12.45-13.45 *Lunch*

- 13.45-14.45 **Practical session on OMICS data**
- 14.45-15.00 **Introduction to pharmacometrics**
Georg Hempel, Institut für Pharmazeutische und Medizinische Chemie, -
Klinische Pharmazie, Westfälische Wilhelms-Universität Münster, Münster,
Germany
- 15.00-15.25 **Pharmacometrics with immunotherapy**
Joseph Ciccolini, Pharmacokinetics Laboratory, Centre de Recherche en
Cancérologie de Marseille, Aix-Marseille Université, Marseille, France
- 15.25-15.50 **PK, PD, first dose and schedule selection in phase I**
Eric Raymond, Oncologie Médicale, Centre Hospitalier Paris Saint-Joseph
Paris, France
- 15.50-16.05 *Coffee break*
- 16.05-16.30 **New types of clinical studies**
Axel Hanauske, Global Early Drug Development Lilly Oncology, Germany
- 16.30-17.30 **Final discussion with Q&A**
- 19.00 **EORTC-PAMM Winter Meeting, Welcome Cocktail**

THURSDAY 7TH FEBRUARY

SESSION I: THE MODERN LANDSCAPE AND NEW AVENUES IN THE TREATMENT OF MALIGNANCIES

Chairs: Erik Raymond, France and Nadia Zaffaroni, Italy

8.30-9.00	Inhibitors of deubiquitinases: from preclinical to clinical studies Stig Linder, Karolinska Institute, Linköping University, Sweden
9.00-9.30	Host-Microbe Co-metabolism and Cancer Drug Efficacy Filipe Cabreiro, Birkbeck University of London, United Kingdom
9.30-10.00	The role of the microbiome in immunotherapy Lisa Derosa, Institut Gustave Roussy, France
10.00-10.30	Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Marina Kreutz, University of Regensburg, Germany
10.30-11.00	<i>Coffee break, poster viewing</i>
11.00-11.30	Next generation histopathological diagnosis: from omics to clinical applications Aldo Scarpa, University of Verona, Italy
11.30-12.00	Does the dose of monoclonal antibody make matter? Etienne Chatelut, University of Toulouse, France
12.00-12.30	Is pharmacometrics the missing link of immunotherapy? Joseph Ciccolini, University of Marseille, France
12.30-13.00	The immune suppressive myeloid environment in cancers Vincenzo Bronte, University of Verona, Italy
13.00-14.00	<i>Lunch, , poster viewing</i>

SESSION II: GASTRO-INTESTINAL CANCERS

Chairs: Annette Larsen, France and Alfredo Guglielmi, Italy

14.00-14.30	Introductory remarks Elizabeth Smyth, Cambridge University Hospital NHS Foundation Trust, UK
14.30-15.00	TAK-ing aim at chemoresistance: the role of TGF beta pathway as therapeutic target in digestive tumors Davide Melisi, University of Verona, Italy
15.00-15.30	TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression Adam Frampton, Imperial College of London, UK
15.30-16.00	The new ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up of gastrointestinal stromal tumours Iwona Lugowska, MSCMI, Warsaw, Poland
16.00-16.30	<i>Coffee break, , poster viewing</i>
16.30-17.00	New therapeutic opportunities from DNA damage repair to immunotherapy in pancreatic cancer Giampaolo Tortora, Catholic University of Rome, Italy
17.00-17.30	Surgery as adjuvant treatment in pancreatic cancer? Claudio Bassi, University of Verona, Italy

SATELLITE SYMPOSIUM SERVIER (NO ECM)

Chair: Godefridus J. Peters, The Netherlands and Andrea Bonetti, Italy

17.30-18.15	Present and future of Trifluridine/Tipiracil Mario Scartozzi, University of Cagliari, Italy
18.15-18.45	Presentation of three clinical cases Alessandra Auriemma, Italy Michele Pavarana, Italy Jacopo Giuliani, Italy
18.45-19.00	Discussion and closure

FRIDAY 8TH FEBRUARY

SESSION III: NEW CHALLENGES IN DRUG'S RESISTANCE MECHANISMS

Chairs: Etienne Chatelut, France and Paola Perego, Italy

8.30-9.00	Synthetic viability – mechanisms of drug resistance in BRCA1/2-deficient mouse mammary tumors Sven Rottenberg, University of Bern, Switzerland
9.00-9.30	Evolution and characterization of carboplatin resistance at single cell resolution Oliver Harismendy– UCSD, La Jolla, CA, USA
9.30-10.00	Oncogenic Signaling Pathways in The Cancer Genome Atlas Giovanni Ciriello, University of Lausanne, Switzerland
10.00-10.30	<i>Coffee break, , poster viewing</i>

SESSION IV: ORAL COMMUNICATIONS 1

Chairs: Etienne Chatelut, France and Paola Perego, Italy

10.30-10.45	The economic impact of biosimilars in Oncology and Hematology: the case of trastuzumab and rituximab. Jacopo Giuliani, Mater Salutis Hospital, Legnago, Italy
10.45-11.00	New paradigms in the treatment of advanced renal cell carcinoma Camillo Porta, Fondazione Maugeri, Pavia, Italy
11.00-11.15	
11.15-11.30	
11.30-11.45	
11.45-12.00	
12.00-12.15	

LECTURE **ECM**

12.15-13.00	Mutational model in oncology: a new paradigm for the future? Nello Martini, Presidente Fondazione Ricerca e Salute, Italy
13.00-14.00	<i>Lunch, poster viewing</i>

SESSION V: THORACIC CANCERS

Chairs: Alberto Amadori, Italy and Michele Milella, Italy

14.00-14.30	Introductory remarks Benjamin Besse, Gustave Roussy Cancer Campus, Paris, France
14.30-15.00	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives Emilio Bria, Catholic University of Rome, Italy
15.00-15.30	Splicing modulation as novel therapeutic strategy against diffuse malignant pleural and peritoneal mesothelioma Elisa Giovannetti, Dept. Medical Oncology CCA, Amsterdam, The Netherlands
15.30-16.00	<i>Coffee break</i>

SESSION VI: ORAL COMMUNICATIONS 2

Chairs: Alberto Amadori, Italy and Michele Milella, Italy

16.00-16.15	
16.15-16.30	
16.30-16.45	
16.45-17.00	
17.00-17.15	
17.15-17.30	

LECTURE ECM

17.30-18.00	Cancer in movies and literature Luciano Defiore, Sapienza University, Rome, Italy
-------------	---

18.00 **PAMM meeting NO ECM**

20.30 ***Social Dinner***

SATURDAY 9TH FEBRUARY

SESSION VII: BREAST CANCER

Chairs: Franco Muggia, USA and Stefania Gori, Italy

8.30-9.00	Introductory remarks Etienne Brain, Institut Curie, Hopital Rene Huguenin, Paris, France
9.00-9.30	Closing the gap between precision biology and personalized cancer medicine: the example of HER2 positive early breast cancer Pierfranco Conte, Istituto Oncologico Veneto and University of Padua, Italy
9.30-10.00	Multi-gene testing: from tissue to liquid biopsy in breast cancer Gabriele Zoppoli, University of Genova, Italy
10.00-10.15	Optimizing CDK 4/6 inhibitors in breast cancer Andrea Bonetti, Mater Salutaris Hospital, Legnago, Italy
10.15-10.30	<i>Coffee break</i>

SESSION VIII: HAEMATOLOGICAL MALIGNANCIES

Chairs: Giovanni Martinelli and Fabio Benedetti, Italy

10.30-11.00	Current advancements and future challenges in paediatric haematology oncology Simone Cesaro, University Hospital of Verona, Italy
11.00-11.30	Targeting bone marrow stromal support to haematological malignancies Mauro Krampera, University of Verona, Italy
11.30-12.00	Pharmacometric considerations in the treatment of leukaemia in children Georg Hempel, University of Münster, Germany

THE BURGER-KELLAND LECTURE

12.00-12.45	From targeted therapy to targeted therapy Godefridus J. Peters, The Netherlands
-------------	---

12.45 POSTER PRIZE AND CLOSURE

MEETING PLANNER

RENBEL GROUP
tailor-made professional services



Renbel Travel Srl
Via Valpolicella, 1
37124 Verona | Italy
Tel. +39 045 7701150
events@renbelgroup.it

Platinum Sponsorship



Gold Sponsorship



Silver Sponsorship

